Immunoassay Reagent AdviseDx SARS-CoV-2 IgM For Alinity i System 200 Tests

Features

• The AdviseDx SARS-CoV-2 IgM Assay is for use under an FDA EUA only: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations
• Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C 263a, that meet requirements to perform moderate or high complexity tests
• The AdviseDx SARS-CoV-2 IgM assay is a chemiluminescent microparticle immunoassay (CMIA) intended for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum, serum separator tube, and plasma (dipotassium EDTA, tripotassium EDTA, lithium heparin, lithium heparin separator tube, sodium heparin)
• At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity; AdviseDx SARSCoV-2 IgM assay should not be used to diagnose acute SARS-CoV-2 infection
• Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities
• Negative results do not preclude acute SARSCoV-2 infection; if acute infection is suspected, direct testing for SARS-CoV-2 is necessary
• False positive results for the AdviseDx SARS-CoV-2 IgM assay may occur due to cross-reactivity from pre-existing antibodies or other possible causes
• Due to the risk of false positive results, confirmation of positive results should be considered using a second, different IgM assay

More Information

• AdviseDx SARS-CoV-2 IgM FDA EUA Letter
• AdviseDx SARS-CoV-2 IgM for use with Alinity i System IFU
• AdviseDx SARS-CoV-2 IgM Healthcare Providers Fact Sheet
• AdviseDx SARS-CoV-2 IgM Recipients Fact Sheet